Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

November 15, 2005 08:00 ET

Miraculins to Present Prostate Diagnostic at International Cancer Conference

WINNIPEG, MANITOBA--(CCNMatthews - Nov. 15, 2005) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of biomarkers and diagnostics for select cancers, is pleased to announce that the Company will be presenting data from its ongoing prostate cancer diagnostic project at the International Conference on Molecular Targets and Cancer Therapeutics, co-organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) at the Pennsylvania Conference Center in Philadelphia, from November 14-18.

The Company will be presenting results from discovery work conducted on urine samples from 184 human volunteers, including 66 positive for prostate cancer, 42 diagnosed with BPH (benign prostatic hyperplasia) and 76 healthy controls. The presentation will include data on promising markers to be included in Miraculins' prostate cancer diagnostic test. These markers have been selected on the basis of their correlation to prostate cancer, and their absence of correlation to other confounding factors such as age, use of medication and secondary conditions.

The poster will report that in the training set, Miraculins was able to attain sensitivity and specificity results of greater than 90% respectively using various diagnostic algorithms. The diagnostic panels developed with these biomarkers are significantly better than current screening methods. Specifically, the panels described in the poster are approximately three times more sensitive and 50% more specific than total PSA test results on the same samples. PSA is the current diagnostic standard and remains recommended for frontline prostate cancer screening by the American Cancer Society. Miraculins is currently validating the classification algorithms in larger sets of samples. Final classification results will be contingent on these studies.

"We are excited about this opportunity to share our findings with the scientific community at large," commented Dr. Jim Charlton, Miraculins' Vice President, Research. "This public presentation reflects our excitement about what Miraculins has been able to accomplish and our belief that we can commercialize diagnostic tools to improve cancer diagnosis."

Dr. Vincent Lenaerts, President of Miraculins, commented, "We are very pleased with the timely progression of our prostate cancer test; the peer review process of this world-class conference is a recognition of our scientific accomplishments."

Miraculins continues to work towards the development of a commercially available diagnostic panel for prostate cancer using the markers highlighted in this poster presentation. The Company is presently validating its diagnostic methods in a larger sample set, while concurrently preparing its regulatory strategy.

The American Association for Cancer Research, founded in 1907, is a nonprofit society of more than 23,000 laboratory, translational, and clinical cancer researchers. Its mission is to prevent and cure cancer through research, education, and communication.

About Miraculins Inc.

Miraculins is a biotechnology company focused on research and development using its proprietary BEST™ platform for the screening and identification of target proteins and peptides related to diseases. The Company is developing products for the diagnosis and treatment of select cancers. Its lead product focuses on improving the diagnosis of prostate cancer.

Prostate cancer is responsible for greater than 240,000 new diagnoses in North America each year. The current screening standard for prostate cancer, PSA, is ineffective at reliably distinguishing between non-life threatening prostate conditions and critical prostate cancer. In spite of this fact, there are greater than 25 million PSA tests performed annually in the United States alone, resulting in one million prostate biopsy procedures. An estimated 75% of these procedures are unnecessary and could be avoided if a superior alternative to PSA were available.

The Company continues to evaluate opportunities to expand its focus and initiate studies in additional disease conditions and recently initiated a study for the development of a diagnostic for breast cancer. Miraculins has also recently acquired a number of complimentary patents, creating opportunities for the Company in numerous additional cancer areas.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information